Hypertension in pregnancy: Taking cues from pathophysiology for clinical practice

Clinical Cardiology

Volumn 41, Issue 2, 2018, Pages 220-227

  Sava, Ruxandra I ^a,b   March, Keith L ^a   Pepine, Carl J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Decidual Natural Killer Cells; Extravillous Trophoblast Cells; Hypoxia; Incomplete Materno Fetal Immune Tolerance; Preeclampsia

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

BED REST; CLINICAL PRACTICE; CYTOTROPHOBLAST; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EXERCISE; FEMALE; FETUS OUTCOME; FETUS RISK; GENETIC LINKAGE; HIGH RISK INFANT; HIGH RISK PREGNANCY; HUMAN; HYPOXIA; IMMUNOLOGICAL TOLERANCE; MATERNAL HYPERTENSION; NOTCH SIGNALING; ORGAN INJURY; PATHOPHYSIOLOGY; PLACENTAL HYPOXIA; PREECLAMPSIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMALL FOR DATE INFANT; BLOOD PRESSURE; DISEASE MANAGEMENT; GLOBAL HEALTH; INCIDENCE; PHYSIOLOGY; PREGNANCY; SURVIVAL RATE; TRENDS;

BLOOD PRESSURE; DISEASE MANAGEMENT; FEMALE; GLOBAL HEALTH; HUMANS; INCIDENCE; PRE-ECLAMPSIA; PREGNANCY; RISK ASSESSMENT; SURVIVAL RATE;

EID: 85042542973     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22892     Document Type: Review

References (50)

1. Vest AR, Cho LS. Hypertension in pregnancy. Curr Atheroscler Rep. 2014;16:395.
2. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–1131.
3. Breathett K, Muhlestein D, Foraker R, et al. Differences in preeclampsia rates between African American and Caucasian women: trends from the National Hospital Discharge Survey. J Womens Health (Larchmt). 2014;23:886–893.
4. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–799.
5. Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753.
6. Melchiorre K, Sutherland G, Sharma R, et al. Mid-gestational maternal cardiovascular profile in preterm and term pre-eclampsia: a prospective study. BJOG. 2013;120:496–504.
7. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human pregnancy: facts and controversies. Placenta. 2006;27:939–958.
8. Huppertz B, Gauster M, Orendi K, et al. Oxygen as modulator of trophoblast invasion. J Anat. 2009;215:14–20.
9. Smith SD, Dunk CE, Aplin JD, et al. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. Am J Pathol. 2009;174:1959–1971.
10. Inngjerdingen M, Kveberg L, Naper C, et al. Natural killer cell subsets in man and rodents. Tissue Antigens. 2011;78:81–88.
11. Wallace AE, Host AJ, Whitley GS, et al. Decidual natural killer cell interactions with trophoblasts are impaired in pregnancies at increased risk of preeclampsia. Am J Pathol. 2013;183:1853–1861.
12. Palei AC, Spradley FT, Warrington JP, et al. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf). 2013;208:224–233.
13. Fraser R, Whitley GS, Johnstone AP, et al. Impaired decidual natural killer cell regulation of vascular remodelling in early human pregnancies with high uterine artery resistance. J Pathol. 2012;228:322–332.
14. Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med. 2006;12:1065–1074.
15. Elfarra J, Amaral LM, McCalmon M, et al. Natural killer cells mediate pathophysiology in response to reduced uterine perfusion pressure. Clin Sci (Lond). 2017;131:2753–2762.
16. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69:1–7.
17. Saftlas AF, Rubenstein L, Prater K, et al. Cumulative exposure to paternal seminal fluid prior to conception and subsequent risk of preeclampsia. J Reprod Immunol. 2014;101-102:104–110.
18. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856–2869.
19. Hiby SE, Walker JJ, O'Shaughnessy K M, et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200:957–965.
20. Moffett A, Chazara O, Colucci F, et al. Variation of maternal KIR and fetal HLA-C genes in reproductive failure: too early for clinical intervention. Reprod Biomed Online. 2016;33:763–769.
21. Hunkapiller NM, Gasperowicz M, Kapidzic M, et al. A role for Notch signaling in trophoblast endovascular invasion and in the pathogenesis of pre-eclampsia. Development. 2011;138:2987–2998.
22. Zhao WX, Wu ZM, Liu W, et al. Notch2 and Notch3 suppress the proliferation and mediate invasion of trophoblast cell lines. Biol Open. 2017;6:1123–1129.
23. Halasz M, Szekeres-Bartho J. The role of progesterone in implantation and trophoblast invasion. J Reprod Immunol. 2013;97:43–50.
24. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989;161:1200–1204.
25. Goulopoulou S, Davidge ST. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. Trends Mol Med. 2015;21:88–97.
26. Iriyama T, Wang W, Parchim NF, et al. Hypoxia-independent upregulation of placental hypoxia inducible factor-1alpha gene expression contributes to the pathogenesis of preeclampsia. Hypertension. 2015;65:1307–1315.
27. Tal R. The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod. 2012;87:134.
28. Atallah A, Lecarpentier E, Goffinet F, et al. Aspirin for prevention of preeclampsia. Drugs. 2017;77:1819–1831.
29. Haram K, Mortensen JH, Nagy B. Genetic aspects of preeclampsia and the HELLP syndrome. J Pregnancy. 2014;2014:910751. https://doi.org/10.1155/2014/910751
30. van Dijk M, van Bezu J, van Abel D, et al. The STOX1 genotype associated with pre-eclampsia leads to a reduction of trophoblast invasion by alpha-T-catenin upregulation. Hum Mol Genet. 2010;19:2658–2667.
31. Li X, Tan H, Chen M, et al. Transforming growth factor beta 1 related gene polymorphisms in gestational hypertension and preeclampsia: a case-control candidate gene association study [published online November 23, 2017]. Pregnancy Hypertens. https://doi.org/10.1016/j.preghy.2017.11.010.
32. Poon LC, Nicolaides KH. Early prediction of preeclampsia. Obstet Gynecol Int. 2014;2014:297397.
33. Roberge S, Giguere Y, Villa P, et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29:551–556.
34. Magro-Malosso ER, Saccone G, Di Tommaso M, et al. Exercise during pregnancy and risk of gestational hypertensive disorders: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2017;96:921–931.
35. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines [published online November 7, 2017]. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2017.11.006.
36. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2003;(3):CD002863.
37. Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:407–417.
38. Cleary KL, Siddiq Z, Ananth CV, Wright JD, Too G, D'Alton ME, Friedman AM. Use of antihypertensive medications during delivery hospitalizations complicated by preeclampsia. Obstet Gynecol. 2018 Feb 5. https://doi.org/10.1097/AOG.0000000000002479.
39. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124:940–950.
40. Li H, Ohta H, Tahara Y, et al. Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model. Sci Rep. 2015;5:15271.
41. Bowles AC, Wise RM, Gerstein BY, et al. Immunomodulatory effects of adipose stromal vascular fraction cells promote alternative activation macrophages to repair tissue damage. Stem Cells. 2017;35:2198–2207.
42. Ghannam S, Pene J, Moquet-Torcy G, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185:302–312.
43. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516–525.
44. Ditisheim A, Wuerzner G, Ponte B, et al. Prevalence of hypertensive phenotypes after preeclampsia: a prospective cohort study. Hypertension. 2018;71:103–109.
45. Bonamy AK, Parikh NI, Cnattingius S, et al. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. Circulation. 2011;124:2839–2846.
46. Orabona R, Vizzardi E, Sciatti E, et al. Maternal cardiac function after HELLP syndrome: an echocardiography study. Ultrasound Obstet Gynecol. 2017;50:507–513.
47. Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation. 2014;129:1254–1261.
48. Chen KH, Seow KM, Chen LR. Progression of gestational hypertension to pre-eclampsia: a cohort study of 20,103 pregnancies. Pregnancy Hypertens. 2017;10:230–237.
49. Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186:66–71.
50. Park K, Quesada O, Cook-Wiens G, et al. Adverse pregnancy outcomes are associated with reduced coronary flow reserve in women with signs and symptoms of ischemia without obstructive coronary disease. Circulation. 2017;136:A14676.